
PKU GOLIKE
About PKU GOLIKE
PKU GOLIKE is a Healthcare company founded in 2022, and was acquired by Eton Pharmaceuticals in March 2024. Company offers pre measured packets and bars containing amino acids for the dietary management of phenylketonuria. Its chief executive, as recorded, is Michelle Lock. Its focus areas include Pharmaceutical Product Websites. Its legal entity is Eton Pharmaceuticals.
Company details
PKU GOLIKE was established in 2022 as a product line in the medical nutrition sector, focused on dietary support for phenylketonuria. Coated granule formulations of 19 essential amino acids are delivered through pre-measured packets and bars, designed for gradual release and absorption. Operations center on product availability in the United States, introduced in October 2022, with Michelle Lock serving as CEO.
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website pkugolike.com
- Social LinkedIn Facebook Instagram
- Acquired by Eton Pharmaceuticals (Mar 2024)
- Legal Name Eton Pharmaceuticals
- Investors
- Acquired byEton Pharmaceuticals
(Mar 2024)
Investors in PKU GOLIKE
PKU GOLIKE has secured backing from 1 investor. Prominent investors backing the company include Eton Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sterile injectables are developed and commercialized by Eton Pharmaceuticals. | 2013 | etonpharma.com | Barrington, United States |
Investor details for PKU GOLIKE
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PKU GOLIKE
1 people are tracked at PKU GOLIKE (1 in leadership).
| Name | Role | Group |
|---|---|---|
Michelle Lock | CEO | Leadership |
Complete people profiles for PKU GOLIKE
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PKU GOLIKE
2 dated milestones of PKU GOLIKE across 2 years, from founding to its latest funding, stage changes and deals.
- Founded PKU GOLIKE is founded.
- Exit Acquired by Eton Pharmaceuticals.
Web traffic of PKU GOLIKE
The website of PKU GOLIKE (pkugolike.com) receives about 2K visits a month.
- Monthly visits2K
▼ 5% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PKU GOLIKE
PKU GOLIKE was founded in 2022.
Michelle Lock is the CEO of PKU GOLIKE, as recorded in our data.
PKU GOLIKE was established in 2022 as a product line in the medical nutrition sector, focused on dietary support for phenylketonuria. Coated granule formulations of 19 essential amino acids are delivered through pre-measured packets and bars, designed for gradual release and absorption. Operations center on product availability in the United States, introduced in October 2022, with Michelle Lock serving as CEO.
PKU GOLIKE has 1 investor. Key investors include Eton Pharmaceuticals.
PKU GOLIKE operates through Eton Pharmaceuticals.
Yes. PKU GOLIKE was acquired by Eton Pharmaceuticals in March 2024.